Checkpoint inhibitors in immunotherapy of ovarian cancer.
about
Immunotherapy of Ovarian Cancer: The Role of Checkpoint InhibitorsStrategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyThe Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A Systematic ReviewCombined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment.Identification of Key Pathways and Genes in the Dynamic Progression of HCC Based on WGCNA.
P2860
Q26799812-0922C4A3-5988-4570-9A84-FE264876ECC5Q26823515-A0F0BF0A-FE42-4AAD-B7A4-19EDA580203BQ28074666-37E7912C-641D-4B35-B3C3-F870807394CCQ35896426-0CBF1BB1-6566-46EB-8C98-02321DD4F9EEQ39402079-BDAD5D54-4439-4435-9075-F984A44F5E3CQ47398937-CA9F6EFD-B1D6-486A-910F-FCDE6877B5C7Q50002028-61CA8760-C600-422B-9764-B57F9E96120E
P2860
Checkpoint inhibitors in immunotherapy of ovarian cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Checkpoint inhibitors in immunotherapy of ovarian cancer.
@en
type
label
Checkpoint inhibitors in immunotherapy of ovarian cancer.
@en
prefLabel
Checkpoint inhibitors in immunotherapy of ovarian cancer.
@en
P2093
P2860
P1433
P1476
Checkpoint inhibitors in immunotherapy of ovarian cancer.
@en
P2093
Dong-hui Wang
Xiao-hua Wu
P2860
P2888
P356
10.1007/S13277-014-2848-2
P577
2014-11-20T00:00:00Z
P6179
1053541050